Eliana Clark - 01 Mar 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Technical Officer
Signature
James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
01 Mar 2026
Net transactions value
-$8,364
Form type
4
Filing time
03 Mar 2026, 16:16:13 UTC
Previous filing
07 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Clark Eliana EVP, Chief Technical Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE James Basta, attorney-in-fact 03 Mar 2026 0001914448

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +7,353 +8.4% $0.000000 94,471 01 Mar 2026 Direct F1
transaction NTLA Common Stock Sale $8,364 -607 -0.64% $13.78 93,864 02 Mar 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Award $0 +10,505 $0.000000 10,505 01 Mar 2026 Common Stock 10,505 $13.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person.
F3 This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.